These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22937754)

  • 1. Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidence.
    Khattak MA; Fisher RA; Pickering LM; Gore ME; Larkin JM
    BJU Int; 2012 Nov; 110(10):1407-8. PubMed ID: 22937754
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C; Jones RJ
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.
    Pal SK; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):3-5. PubMed ID: 21816688
    [No Abstract]   [Full Text] [Related]  

  • 4. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.
    Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V
    Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival as endpoint in metastatic RCC?
    Knox JJ
    Lancet; 2008 Aug; 372(9637):427-9. PubMed ID: 18653227
    [No Abstract]   [Full Text] [Related]  

  • 6. Temsirolimus for advanced renal-cell carcinoma.
    Fazio N; Dettori M; Lorizzo K
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17804854
    [No Abstract]   [Full Text] [Related]  

  • 7. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M; Douis H; Porfiri E
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
    Rodríguez Faba O; Breda A; Rosales A; Palou J; Algaba F; Maroto Rey P; Villavicencio H
    Eur Urol; 2010 Aug; 58(2):307-10. PubMed ID: 20347211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A uncommon cause of haemoptysis: metastatic collecting duct renal carcinoma.
    Schubert PT; Louw M; Scubert C; Eedes C; Theron J
    Diagn Cytopathol; 2011 Dec; 39(12):938-40. PubMed ID: 22081532
    [No Abstract]   [Full Text] [Related]  

  • 12. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM
    Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
    [No Abstract]   [Full Text] [Related]  

  • 14. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
    Büchler T; Dusek L; Fínek J; Poprach A; Budnáková D; Kandrnal V; Jarkovský J; Bortlícek Z; Klimes D; Abrahámová J; Vyzula R
    Klin Onkol; 2011; 24(5):389-92. PubMed ID: 22070021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of endobronchial metastases of renal cell carcinoma treated with interventional bronchoscopy].
    Ozaydin D; Seğmen F; Aktaş Z; Yilmaz A; Sen N; Demirağ F
    Tuberk Toraks; 2014; 62(1):95-7. PubMed ID: 24814084
    [No Abstract]   [Full Text] [Related]  

  • 18. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract]   [Full Text] [Related]  

  • 19. Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status.
    Broom RJ; Caldwell I; Hanning F; Fong P; Deva S; Oei P
    Clin Genitourin Cancer; 2012 Sep; 10(3):202-6. PubMed ID: 22440786
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
    J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.